Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair loss while taking Mounjaro is reported by some people and is recognised in the medicine's clinical data, but it is not caused by tirzepatide directly attacking hair follicles. The most common explanation is telogen effluvium — a temporary shedding triggered by rapid weight loss rather than by the medicine itself. Clinical trial data and post-market reporting both shed light on how common this is and what tends to happen next. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Hair-related side effects appear in the Mounjaro prescribing information as a recognised finding. In the SURMOUNT-1 trial (which followed 2,539 adults over 72 weeks) alopecia (hair shedding) was listed among the adverse events reported at the higher maintenance doses. The frequency rose at the doses associated with the greatest weight reduction, which supports the view that the scale of calorie deficit matters more than the medicine dose itself. The NHS tirzepatide information page notes hair loss as a known side effect worth discussing with your prescriber if it concerns you.
Telogen effluvium works like this: a significant physical stressor, including rapid weight loss, pushes a larger-than-usual proportion of hair follicles out of the active growth phase and into a resting phase simultaneously. Around two to three months later, those follicles shed, producing what can feel like alarming volume loss in the shower or on the pillow. The hair shaft itself is not damaged; the follicle is still alive. That distinction matters when you are trying to predict what happens next.
The shedding is real, and it can be distressing. That deserves to be said plainly. But the mechanism is the same one that causes post-pregnancy hair loss, a reversible cycle, not permanent follicle death. People who lose weight on Mounjaro most rapidly tend to notice it most, which is, in a sense, a side effect of success.
The appetite suppression that makes tirzepatide effective also makes it easy to eat too little protein and too few micronutrients without noticing. Keratin, the structural protein hair is made from, requires an adequate supply of dietary protein, iron, zinc, and B vitamins to be produced normally. When intake drops sharply, the body redirects limited resources away from non-essential structures like hair and towards vital organs.
This is why two people on the same dose can have very different experiences of Mounjaro's effect on hair: the one prioritising protein at every meal and staying hydrated tends to fare better. A common target in weight-management practice is 1.2–1.5 g of protein per kilogram of target body weight per day, though your prescriber or a registered dietitian should guide your specific intake. Checking a morning routine like taking a multivitamin before the kettle has finished boiling is a small habit that some people find helps them stay consistent.
Iron deficiency is worth mentioning separately. Rapid weight loss can unmask pre-existing low ferritin levels, and low ferritin is itself a recognised cause of diffuse hair shedding independent of tirzepatide. If your hair loss feels significant, your GP can run a blood panel to check ferritin, full blood count, and thyroid function, all relevant causes that are worth ruling out before attributing everything to Mounjaro.
For most people, shedding peaks around the three-to-five month mark and then gradually slows as weight loss decelerates or stabilises. Hair density typically begins recovering within six to twelve months. This pattern mirrors the natural hair cycle: once the follicles return to the growth phase, new hair grows in, though the turnaround is not immediate. People sometimes notice fine regrowth along the hairline before the density across the scalp catches up.
If you are concerned about dryness or texture changes alongside shedding, or if the loss feels patchy rather than diffuse, those patterns can have different causes and are worth discussing with a prescriber or dermatologist. Patchy loss in particular is less typical of telogen effluvium and may warrant investigation.
There is a broader question some people ask about whether the overall experience of hair loss on Mounjaro should influence the decision to continue treatment. For most people, the clinical benefits of meaningful weight loss (improved blood pressure, glycaemic control, joint load, sleep) outweigh a temporary cosmetic side effect. That balance is worth talking through with a clinician rather than resolving alone. You can read more about how Mounjaro affects hair in our dedicated overview, which covers the fuller picture including texture and regrowth timelines.
Understanding the full side-effect profile of tirzepatide is part of what informed prescribing looks like. Our tirzepatide overview covers the mechanism, the evidence and the eligibility criteria in one place. If you are already on treatment and have specific concerns, our clinical team is available for aftercare seven days a week.
Hair loss is one of the questions our prescribers hear regularly from people starting or considering Mounjaro. If you would like a personalised assessment of your suitability for treatment and a chance to ask about side effects before committing, speak to our prescribers via a free consultation, reviewed the same day by a real clinician, never software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.